In vitro activity of anidulafungin. Comparison with the activity of other echinocandins;Actividad in vitro de anidulafungina. Comparación con la actividad de otras equinocandinas

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 14, 2008, Pages 7-13

  Martín Mazuelos, Estrella ^a   Rodríguez Tudela, Juan Luis ^b  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Anidulafungin; Aspergillus; Candida; In vitro resistance

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; PYRROLE DERIVATIVE; TERBINAFINE; VORICONAZOLE; 1,3-BETA-GLUCAN SYNTHASE; ANTIFUNGAL AGENT; BETA 1,3 GLUCAN; BETA GLUCAN; BETA-1,3-GLUCAN; FUNGAL PROTEIN; GLUCOSYLTRANSFERASE; LIPOPEPTIDE;

ASPERGILLUS; ASPERGILLUS NIDULANS; CANDIDA; CELL WALL; COMPARATIVE STUDY; CRYPTOCOCCUS; DRUG ACTIVITY; ENZYME SYNTHESIS; FERMENTATION; FUNGAL CELL; FUNGAL STRAIN; FUSARIUM; IN VITRO STUDY; MUCORALES; MYCOSIS; NONHUMAN; REVIEW; TRICHOSPORON; ANTIFUNGAL RESISTANCE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIOLOGICAL EXAMINATION; SPECIES DIFFERENCE;

ANTIFUNGAL AGENTS; ASPERGILLUS; BETA-GLUCANS; CANDIDA; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; ECHINOCANDINS; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY;

EID: 69249216700     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76587-X     Document Type: Article

References (45)

1. P. De la Torre, and A.C. Reboli Anidulafungin: a new echinocandin for candidal infections Expert Rev Anti Infect Ther 5 2007 45 52 (Pubitemid 46613386)
2. J. Vazquez, and J. Sobel Reviews of antiinfective agents: anidulafungin: a novel echinocandin Clin Infect Dis 43 2006 215 222
3. M.A. Pfaller, L. Boyken, R.J. Hollis, J. Kroeger, S.A. Messer, S. Tendolkar, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance J Clin Microbiol 46 2008 150 156
4. M. Cuenca-Estrella, E. Mellado, T.M. Diaz-Guerra, A. Monzon, and J.L. Rodriguez-Tudela Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B J Antimicrob Chemother 46 2000 475 477 (Pubitemid 30706055)
5. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A-Second edition. 2002. Wayne: National Committee for Clinical Laboratory Standards; 2002.
6. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398-405.
7. B. Almirante, D. Rodriguez, B.J. Park, M. Cuenca-Estrella, A.M. Planes, and M. Almela Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003 J Clin Microbiol 43 2005 1829 1835 (Pubitemid 40491227)
8. A. Gomez-Lopez, A. Alastruey-Izquierdo, D. Rodriguez, B. Almirante, A. Pahissa, J.L. Rodriguez-Tudela, et al. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis. results from population-based surveillance of candidemia in Spain Antimicrob Agents Chemother 52 2008 1506 1509
9. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. 2002. Wayne: National Committee for Clinical Laboratory Standards; 2002.
10. J.L. Rodriguez-Tudela, M.C. Arendrup, S. Arikan, F. Barchisei, J. Bille, E. Chryssantou, et al. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds UCAST 2008
11. S. Arikan, M. Lozano-Chiu, V. Paetznick, and J.H. Rex In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates Antimicrob Agents Chemother 45 2001 327 330 (Pubitemid 32039139)
12. A. Espinel-Ingroff, A. Fothergill, M. Ghannoum, E. Manavathu, L. Ostrosky-Zeichner, and M.A. Pfaller Quality Control and reference guidelines for CLSI broth microdilution method (M38-A Document) for susceptibility testing of anidulafungin against molds J Clin Microbiol 45 2007 2180 2182 (Pubitemid 47203790)
13. E. Martin-Mazuelos Anidulafungin Vicuron IDrugs 6 2003 980 986 (Pubitemid 37321428)
14. M.D. Serrano, A. Valverde-Conde, M. Chaveza, S. Bernal, R.M. Claro, and J. Peman In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp Diagn Microbiol Infect Dis 45 2003 131 135 (Pubitemid 36263026)
15. Z. Odabasi, V.L. Paetznick, J.R. Rodriguez, E. Chen, and L. Ostrosky-Zeichner In vitro activity of anidulafungin against selected clinically important mold isolates Antimicrob Agents Chemother 48 2004 1912 1915 (Pubitemid 38544413)
16. M.A. Pfaller, F. Marco, S.A. Messer, and R.N. Jones In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi Diagn Microbiol Infect Dis 30 1998 251 255 (Pubitemid 28210124)
17. G.G. Zhanel, J.A. Karlowsky, G.A. Harding, T.V. Balko, S.A. Zelenitsky, and M. Friesen In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species Antimicrob Agents Chemother 41 1997 863 865 (Pubitemid 27150550)
18. C. Antachopoulos, J. Meletiadis, T. Sein, E. Roilides, and T.J. Walsh Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia Antimicrob Agents Chemother 52 2008 321 328
19. C. Antachopoulos, J. Meletiadis, T. Sein, E. Roilides, and T.J. Walsh Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species Antimicrob Agents Chemother 51 2007 881 887 (Pubitemid 46355271)
20. J.C. Bowman, G.K. Abruzzo, A.M. Flattery, C.J. Gill, E.J. Hickey, and M.J. Hsu Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans Antimicrob Agents Chemother 50 2006 4202 4205 (Pubitemid 44865171)
21. J. Maertens, I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, and F. Petersen Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis 39 2004 1563 1571 (Pubitemid 39578526)
22. S. Arikan, V. Paetznick, and J.H. Rex Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates Antimicrob Agents Chemother 46 2002 3084 3087 (Pubitemid 34898703)
23. S. Arikan, P. Yurdakul, and G. Hascelik Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp Antimicrob Agents Chemother 47 2003 2640 2643 (Pubitemid 36919471)
24. A. Espinel-Ingroff, B. Arthington-Skaggs, N. Iqbal, D. Ellis, M.A. Pfaller, and S. Messer Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin J Clin Microbiol 45 2007 1811 1820 (Pubitemid 46933912)
25. A. Espinel-Ingroff, and E. Canton Comparison of neo-sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for susceptibility testing of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole and voriconazole J Clin Microbiol 2008 doi: 10.1128/JCM.01883-07 (Pubitemid 351657231)
26. A. Espinel-Ingroff Evaluation of broth microdilution testing parameters and agar diffusion etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991) J Clin Microbiol 41 2003 403 409 (Pubitemid 36098607)
27. A.S. Ibrahim, T. Gebremariam, Y. Fu, J.E. Edwards Jr., and B. Spellberg Combination echinocandin-polyene treatment of murine mucormycosis Antimicrob Agents Chemother 52 2008 1556 1558 (Pubitemid 352009357)
28. A. Philip, Z. Odabasi, J. Rodriguez, V.L. Paetznick, E. Chen, and J.H. Rex In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp Antimicrob Agents Chemother 49 2005 3572 3574 (Pubitemid 41060623)
29. M. Cuenca-Estrella, A. Alastruey-Izquierdo, L. Alcazar-Fuoli, L. Bernal-Martinez, A. Gomez-Lopez, and M.J. Buitrago In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans Antimicrob Agents Chemother 52 2008 1136 1139 (Pubitemid 351358399)
30. M.T. Baixench, N. Aoun, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, and S. Ramires Acquired resistance to echinocandins in Candida albicans: case report and review J Antimicrob Chemother 59 2007 1076 1083 (Pubitemid 47073317)
31. S. Hernandez, J.L. Lopez-Ribot, L.K. Najvar, D.I. McCarthy, R. Bocanegra, and J.R. Graybill Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis Antimicrob Agents Chemother 48 2004 1382 1383 (Pubitemid 38405501)
32. J.N. Kahn, G. Garcia-Effron, M.J. Hsu, S. Park, K.A. Marr, and D.S. Perlin Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase Antimicrob Agents Chemother 51 2007 1876 1878 (Pubitemid 46744179)
33. S. Katiyar, M. Pfaller, and T. Edlind Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility Antimicrob Agents Chemother 50 2006 2892 2894 (Pubitemid 44198725)
34. M. Krogh-Madsen, M. Arendrup, L. Heslet, and J. Knudsen Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically Ill patient Clin Infect Dis 42 2006 938 944
35. M. Laverdiere, R.G. Lalonde, J.G. Baril, D.C. Sheppard, S. Park, and D.S. Perlin Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis J Antimicrob Chemother 57 2006 705 708
36. V. Moudgal, T. Little, D. Boikov, and J.A. Vazquez Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis Antimicrob Agents Chemother 49 2005 767 769 (Pubitemid 40175691)
37. S. Park, R. Kelly, J.N. Kahn, J. Robles, M.J. Hsu, and E. Register Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates Antimicrob Agents Chemother 49 2005 3264 3273 (Pubitemid 41060570)
38. T. Pasquale, J.R. Tomada, M. Ghannoun, J. Dipersio, and H. Bonilla Emergence of Candida tropicalis resistant to caspofungin J Antimicrob Chemother 61 2008 219
39. D.S. Perlin Resistance to echinocandin-class antifungal drugs Drug Resistance Updates 10 2007 121 130
40. E.M. Rocha, G. Garcia-Effron, S. Park, and D.S. Perlin A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus Antimicrob Agents Chemother 51 2007 4174 4176 (Pubitemid 350057823)
41. G. Chamilos, R.E. Lewis, N. Albert, and D.P. Kontoyiannis Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandinspecific and Candida species-related differences Antimicrob Agents Chemother 51 2007 2257 2259 (Pubitemid 46903132)
42. K.V. Clemons, M. Espiritu, R. Parmar, and D.A. Stevens Assessment of the paradoxical effect of caspofungin in therapy of candidiasis Antimicrob Agents Chemother 50 2006 1293 1297
43. D.A. Stevens, M. Espiritu, and R. Parmar Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations Antimicrob Agents Chemother 48 2004 3407 3411 (Pubitemid 39129338)
44. D.A. Stevens, M. Ichinomiya, Y. Koshi, and H. Horiuchi Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for {beta}-1,6-glucan synthesis inhibition by caspofungin Antimicrob Agents Chemother 50 2006 3160 3161 (Pubitemid 44396427)
45. N.P. Wiederhold, D.P. Kontoyiannis, R.A. Prince, and R.E. Lewis Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways Antimicrob Agents Chemother 49 2005 5146 5148